Introduction
World Health Organization (WHO) has declared Tuberculosis as a global emergency in 1993. 1 Multidrug Resistant Tuberculosis (MDR-TB) is defined as resistance of Mycobacterium tuberculosis to Rifampicin and Isoniazid, two of the most effective anti-tubercular drugs for treatment of Tuberculosis. MDR-TB occurs in about 3% in new tuberculosis cases and 12%-17% in previously treated cases. 2 Worldwide, there are an estimated 440 000 people suffering from MDR-TB (2008) with a mortality of 33%. 3 Non-inclusion of two important drugs (Rifampicin and Izoniazid) makes the addition of second line drugs mandatory. These drugs are not only expensive, but have weaker potency, need longer course and have toxic sideeffects compared to conventional anti-TB drugs. The indiscriminate use of first line drugs by doctors and treatment defaulted by patients are main causes for rise in MDR-TB cases. 1 Funding required for MDR-TB control in 2015 will be 16 times higher than that spent in 2010. 3 Presently in India, MDR-TB is managed by medical colleges and private sector. There was no supply of second line drugs until Directly Observed Treatment-Short course (DOTS) Plus (Government launched programme to treat MDR -TB) was launched in August 2007 on pilot basis. Due to financial constraints, MDR-TB patients are often referred for treatment to medical colleges in Mumbai. Unavailability of these drugs on hospital schedule, forces the patients to buy drugs on their own. Early diagnosis and treatment may prevent some complications and deaths. Migrations, unemployment, alcoholism, are important causes for default in TB 5, 6 . Hence there is an urgency for early diagnosis of MDR-TB and its appropriate management guided by Drug Susceptibility Tests (DST). 7 The individual costs for various tests and medications incurred for Tuberculosis treatment using Category I, II and III are Rs.1587/-, Rs.1924/-and Rs.1417/-respectively. 8 The term -Programmatic Management Of Drug Resistant TB‖ (PMDT) (DOTS Plus) is a programme based guideline for MDR -TB diagnosis, management and treatment. These guidelines promote full integration of early TB management and PMDT activities under the Revised National Tuberculosis Control Programme (RNTCP). 9 In India, the patients treated in the private sector depend on their own family income for the cost of physician, investigations and treatment of MDR-TB. The income of the entire family is drained. These efforts will cure the disease only in 33-50% patients. The rest may develop Extensively Drug Resistant TB (XDR-TB) or die.
The Editorial of the Indian Journal Of Tuberculosis -2005 states that the cost of MDRTB is about US$ 1600 compared to less than US$ 10 for RNTCP DOTS treatment. 10 The problems encountered during the treatment of MDR TB is the sustenance of funds and drugs for continuation of treatment; while monitoring the compliance to treatment and managing adverse drug reactions to second line anti TB drugs. There is an urgent need for establishment of more Reference Laboratories to perform mycobacterium culture growth and DST and the development of Rapid On-site line probe assay which will diagnose MDR-TB early especially in new cases. Proper implementation of DOTS regimen can reduce the incidence of non-compliance and those developing MDR-TB can be covered under DOTS PLUS regimen to reduce financial burden on the family. Exclusion criteria: Between 18 to 60 yrs of age
Objectives
After written informed consent, data was collected from the patients. The detailed evaluation of the cost in terms of cost incurred for diagnosis, treatment and follow-up visits in this institute was recorded. The sources of income and per capita income were calculated. Detailed history about the source for procurement of medicines required for MDR-TB treatment was collected.
Sampling method: Non-Probability Purposive sampling However, the following points must be noted while formulating the MDR -TB regimen in cost management: a) Two drugs should not belong to same drug family -they cause added toxicity with no additional benefit b) Potent drugs should be preferred over less potent drugs in the regimen c) Drugs with lesser side effects should be chosen (better tolerated by the patient) 
ijsr.net
Licensed Under Creative Commons Attribution CC BY d) At least 3-4 drugs (not used earlier) must be added to ensure good potent regimen e) Certain drugs are potent (bactericidal) and cheap (Levofloxacin is an excellent anti-TB drug which is bactericidal and also cheap -Rs.7/-per day) f) Drugs available in hospital supply should be preferred to bring down the cost of the treatment (Amikacin is available in hospital supply; although it is expensive when purchased by the patient). g) Clofazimine though less potent has an excellent sensitivity and is also cheap. It is better tolerated by the patient (except skin discoloration).
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Sources of Funds
The mean average family income was Rs.8333.33 per month. The mean family size was 5.47. The per capita income of the group was Rs.1473.67
The social & religious groups contributed about Rs. 71380/-in all.
Certain drugs were available as antibiotics from hospital supply. (eg -Injection Amikacin and Azithromycin for indoor patients and oral Levofloxacin for indoor and outdoor patients (OPD).
Most of the patients contributed for second line drugs from their own household income. Some patients borrowed funds from their relatives and friends on loan basis.
The Hospital Poor Box Fund contributed to some funds in procuring medicines for some of the indoor patients. The patients were assessed by Medical social worker; based on their socioeconomic status provided discounts up to 50-75%; the rest being provided from the Hospital Poor Box Fund.
The pharmaceutical companies and the medical stores helped patients in procuring the drugs.
Patients would get up to 10-20% discounts when they directly procured drugs from the wholesalers of the companies (Stockists). Some patients brought medicines from medical stores around the hospital procured the medicines for a discount of 5-10%. This reduction on Maximum Retail Price (MRP) would definitely bring down the cost of total treatment by 10%. Some companies provided drug samples which helped patients tide over few days until money was arranged leading to uninterrupted drug supply.
Discussion
The present study was conducted to determine the total cost of MDR-TB management. In thirteen countries of Central and Eastern Europe (CEEUR), the frequency of MDR-TB was higher in all age groups compared with the rest of the countries (all high-income) and peaked in young adulthood 3 . In this study, the age group was mainly in less than 40 years. The present study excludes indirect cost loss of daily wages and the amount spent by the hospital on the patient for either OPD consultation or indoor stay; unlike -Thorax 2000‖ UK study, 8 where the indirect costs borne by the hospital (OPD & IPD services) were added to the cost incurred in treating MDR TB. TB inflicts considerable economic burden on the overall health system. This information is vital for policy makers and planners to allocate adequately to the programme. 10, 11 Though Clofazimine is considered as a weak anti-TB drug, its response in combination with other anti-TB drugs has been found to be good.12 In this study, Clofazimine was found to cut down the cost of the entire regimen and well tolerated the drug. In a study in the UK, cost of sensitive tuberculosis was 6040 pounds; while cost of resistant tuberculosis was in excess of 60,000 pounds. 8 In a Bangalore study amongst the TB patients, the percentage of patients belonging to low and middle standard of living were 50% and 39% respectively; while the household per capita income of 77% was less than US$1 per day. The costs incurred for diagnosis amounted to US$145; while during RNTCP treatment the cost was US$21. Those people treated outside RNTCP was US$127. This study shows the economic plight of the Indian population suffering from Tuberculosis. 14 International TB funding suffered a setback on contributions from UK. 15 In a study conducted in Ecuador by the Pediatrics Department (Canada), among 104 non-MDR-TB patients, average cost of 104 non-MDR TB treatment was US$960 per patient, as against that the average cost of 14 MDR patients was US$6880. 
Conclusions
1) The average treatment cost of MDR-TB is Rs.
140752.50.This includes total drug costs of Rs.129406.17 2) The average total daily cost of drugs is Rs.166.83.
3) The total cost of treatment is reduced remarkably by including sensitive first line drugs like Pyrazinamide and Ethambutol. They are also more potent and less toxic than the second line drugs. 4) The non-drug expenditure of treatment like blood and microbiological investigations, radiological monitoring will cut down cost in a teaching hospital than private sector. 5) 90% of patients were below forty years of age (an economically productive age group). 6) Average monthly income of the family is Rs. 8333.33; while per capita income is Rs. 1473.67 7) Major contribution towards treatment expenditure comes from patient's personal income. Additional contributions come from socio-religious groups, hospital poor box fund, pharmaceutical companies and medical stores. There were no financial assistance received for this study from any Institute or pharmaceutical company.
